Advertisement

D2 lymphadenectomy in the management of gastric cancer

  • JA McCullough
  • D Evoy
  • KJ Sweeney
  • C Meyers
  • N Ravi
  • N Keeling
  • PJ Byrne
  • JV Reynolds
Original Papers

Abstract

Background Gastric carcinoma is a significant cause of death in Ireland. Surgery offers the best option of cure, but the five-year survival following resection remains dismal at 10–15%. Experience from Japan and from some Western units suggest that an extended (D2) lymphadenectomy in association with gastrectomy increases the prospect of cure, but concern about the morbidity and mortality of this operation and lack of evidence from randomised studies has limited its acceptance.

Aims This study reports the experience of a specialist upper gastrointestinal unit with D2 gastrectomy in a four-year audit.

Methods Sixty-two resections were performed for gastric cancer. Results Nineteen patients were deemed unsuitable for the D2 procedure and underwent a more limited lymphadenectomy (DO or D1). Forty-three patients underwent D2 resection, 12 with an oesophagogastrectomy, 22 with total gastrectomy and nine with a sub-total distal resection. Eight patients undergoing D2 resection had extended resections, five with splenectomy and three with a distal pancreatectomy. Post-operative complications occurred in 31% of patients. Thirty-day and 90-day mortality were zero. Median survival was 822 days in the D2 group (range 120–1,320).

Conclusions These results show that a D2 gastrectomy can be performed with a low morbidity and mortality and a median survival of greater than two years.

Keywords

Gastric Cancer Distal Pancreatectomy Splenic Hilum Distal Pancre Splenic Resection 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. 1.
    National Cancer Registry Ireland. Cancer in Ireland 1997: A Summary.Google Scholar
  2. 2.
    Sobin LH and Witekind C (eds) TNM Classification of Malignant Tumours. 5th edition. New York: John Wiley & Sons, Inc., 1997.Google Scholar
  3. 3.
    Ashley SW, Evoy D, Daly JM. Stomach. In: Principles of suigery (7th Edition). Ed. Schwartz I. McGraw Hill, 1999: 1181–216.Google Scholar
  4. 4.
    Nobrega FT, Sedlack JD, Sedlack RE, Dockerty MB, Ilstrup DM, Kurtland LT. A decline in carcinoma of the stomach. A diagnostic artifact?Mayo Clinical Proceedings 1983; 54(4): 255–60.Google Scholar
  5. 5.
    Ekstrom AM, Hansson LE, Signorello LB, Lindgren A, Beigstrom R, Nyren O. Decreasing incidence of both major histological sub-types of gastric adenocarcinoma: a population-based study in Sweden.Br J Cancer 2000; 83(3): 391–6.PubMedCrossRefGoogle Scholar
  6. 6.
    McKinney A, Sharp L, MacFarlane GJ, Muir CS. Oesophageal and gastric cancer in Scotland.Br J Cancer 1995; 71(2): 411–5.PubMedGoogle Scholar
  7. 7.
    Japanese Research Society for Gastric Cancer. Japanese Classification of Gastric Carcinoma. 1st English Edition. Tokyo: Kanehara, 1995.Google Scholar
  8. 8.
    Kodama Y, Sugimachi K, Soejima K. Evaluation of extended lymph node dissection for carcinoma of the stomach.World J Surg 1981; 5: 241–8.PubMedCrossRefGoogle Scholar
  9. 9.
    Sasako M. Risk factors for surgical treatment in the Dutch gastric cancer trial.Br J Surg 1997; 84: 1567–71.PubMedCrossRefGoogle Scholar
  10. 10.
    Cuschieri A, Fayers P, Fielding J, Craven J, Bancewicz J, Joypaul V, Cook P. Postoperative morbidity and mortality after Dl and D2 resections for gastric cancer: preliminary results of the MRC randomised controlled surgical trial.Lancet 1996; 347: 995–9.PubMedCrossRefGoogle Scholar
  11. 11.
    Bonenkamp JJ, Hermans J, Sasako M, van de Velde CJH. Extended lymph node dissection for gastric cancer.New Engl J Med 1999; 340: 908–14.PubMedCrossRefGoogle Scholar
  12. 12.
    Siewert JR, Stein HJ. Classification of adenocarcinoma of the oesophagogastric junction.Br J Surg 1998; 85: 1457–9.PubMedCrossRefGoogle Scholar
  13. 13.
    Wanebo HJ, Kennedy BJ, Winchester DP, Fregmen A, Stewart AK. Gastric carcinoma: does lymph node dissection alter survival?J Amer Coll Surg 1996; 183: 616–24.Google Scholar
  14. 14.
    Sue-Ling HM, Johnston D, Martin IG, Dixon MF, Landsown MRJ, McMahon MJ, Axon ATR. Gastric cancer: a curable disease in Britain.Br Med J 1993; 307: 591–6.CrossRefGoogle Scholar
  15. 15.
    Degiuli M, Sasako M, Ponti A, Soldati T, Danese F, Calvo F. Morbidity and mortality after D2 gastrectomy for gastric cancer: results of the Italian gastric cancer study group prospective multicentre surgical study.Clin Oncol 1998; 16: 1490–3.Google Scholar
  16. 16.
    Noguchi Y, Yoshikawa T, Tsuburaya A, Motohashi H, Karpeh MS, Brennan MF. Is gastric cancer different between Japan and the United States?Cancer 2000; 89(11): 2237–46.PubMedCrossRefGoogle Scholar
  17. 17.
    Allum WH, Powell DJ, McConkey CC, Fielding JWL. Gastric cancer: a 25 year review.Br J Surg 1989; 76: 535–40.PubMedCrossRefGoogle Scholar

Copyright information

© Springer London 2003

Authors and Affiliations

  • JA McCullough
    • 1
  • D Evoy
    • 1
  • KJ Sweeney
    • 1
  • C Meyers
    • 1
  • N Ravi
    • 1
  • N Keeling
    • 1
  • PJ Byrne
    • 1
  • JV Reynolds
    • 1
  1. 1.Department of Surgery, Trinity Centre for Health SciencesSt James’s HospitalDublin 8Ireland

Personalised recommendations